• 1
    Kontzoglou K, Moulakakis KG, Konofaos P, Kyriazi M, Kyroudes A, Karakitsos P. The role of liquid-based cytology in the investigation of breast lesions using fine-needle aspiration: a cytohistopathological evaluation. J Surg Oncol. 2005; 89: 75-78.
  • 2
    Bishop JW, MacFarlane K, Cheuvront D, Sims KL. Cell recovery and appearance in thin-layer preparations in nongynecologic cytology. Anal Quant Cytol Histol. 1998; 20: 229-237.
  • 3
    Leung CS, Chiu B, Bell V. Comparison of ThinPrep and conventional preparations: nongynecologic cytology evaluation. Diagn Cytopathol. 1997; 16: 368-371.
  • 4
    Hoda RS. Non-gynecologic cytology on liquid-based preparations: a morphologic review of facts and artifacts. Diagn Cytopathol. 2007; 35: 621-634.
  • 5
    Fadda G, Rossi ED, Mulè A, Miraglia A, Vecchio FM, Capelli A. Diagnostic efficacy of immunocytochemistry on fine needle aspiration biopsies processed by thin-layer cytology. Acta Cytol. 2006; 50: 129-135.
  • 6
    Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet. 2005; 365: 1727-1741.
  • 7
    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998; 351: 1451-1467.
  • 8
    Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 124: 966-978.
  • 9
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
  • 10
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672.
  • 11
    Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28: 2784-2795.
  • 12
    Wolff AC, Hammond ME, Schwartz JN, et al; American Society of Clinical Oncology/College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007; 131: 18-43.
  • 13
    Idirisinghe PK, Thike AA, Cheok PY, et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol. 2010; 133: 416-429.
  • 14
    Bédard YC, Pollett AF. Breast fine-needle aspiration. A comparison of ThinPrep and conventional smears. Am J Clin Pathol. 1999; 111: 523-527.
  • 15
    Tabbara SO, Sidawy MK, Frost AR, et al. The stability of estrogen and progesterone receptor expression on breast carcinoma cells stored as PreservCyt suspensions and as ThinPrep slides. Cancer. 1998; 84: 355-360.
  • 16
    Sauer T, Ebeltoft K, Pedersen MK, Kåresen R. Liquid based material from fine needle aspirates from breast carcinomas offers the possibility of long-time storage without significant loss of immunoreactivity of estrogen and progesterone receptors. Cytojournal. 2010; 7: 24.
  • 17
    Konofaos P, Kontzoglou K, Georgoulakis J, et al. The role of ThinPrep cytology in the evaluation of estrogen and progesterone receptor content of breast tumors. Surg Oncol. 2006; 15: 257-266.
  • 18
    Leung SW, Bédard YC. Estrogen and progesterone receptor contents in ThinPrep-processed fine-needle aspirates of breast. Am J Clin Pathol. 1999; 112: 50-56.
  • 19
    Nishimura R, Aogi K, Yamamoto T, et al. Usefulness of liquid-based cytology in hormone receptor analysis of breast cancer specimens. Virchows Arch. 2011; 458: 153-158.
  • 20
    Hanley KZ, Birdsong GG, Cohen C, Siddiqui MT. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations. Cancer. 2009; 117: 279-288.
  • 21
    Williams SL, Birdsong GG, Cohen C, Siddiqui MT. Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations. Int J Clin Exp Pathol. 2009; 2: 476-480.
  • 22
    Sumiyoshi K, Shibayama Y, Akashi S, et al. Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections? Oncol Rep. 2006; 15: 803-808.
  • 23
    Moriki T, Takahashi T, Ueta S, Mitani M, Ichien M. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls. Diagn Cytopathol. 2004; 30: 251-256.
  • 24
    Kumar SK, Gupta N, Rajwanshi A, Joshi K, Singh G. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma. Cytopathology. 2011; doi:10.1111/j.1365-2303.2011.00853.x.
  • 25
    Bédard YC, Pollett AF, Leung SW, O'Malley FP. Assessment of thin-layer breast aspirates for immunocytochemical evaluation of HER2 status. Acta Cytol. 2003; 47: 979-984.
  • 26
    Beatty BG, Bryant R, Wang W, et al. HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol. 2004; 122: 246-255.